Indeed, the widely studied IFN signature is highly variable between patients [11] and it is associated with differences in response to treatments which target it, as has been reported for example in the phase-II results of Sifalimumab clinical trial for SLE patients [12]. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.